Status:
COMPLETED
COVID-19 in Patients With Chronic Liver Diseases
Lead Sponsor:
Stanford University
Conditions:
COVID-19
Chronic Liver Disease
Eligibility:
All Genders
18+ years
Brief Summary
This study seeks to determine how COVID-19 affects the clinical outcome of patients with chronic liver disease, and whether the clinical course of COVID-19 is influenced by underlying chronic liver di...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of COVID-19
- Personal history of either
- Chronic hepatitis C
- Chronic hepatitis B
- Alcoholic liver disease
- Non alcoholic liver disease
- Autoimmune hepatitis, Primary biliary cholangitis, Primary sclerosing cholangitis
- Cryptogenic cirrhosis
- Hepatocellular carcinoma
Exclusion
- Non-COVID-19 patient
Key Trial Info
Start Date :
March 6 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2021
Estimated Enrollment :
1025 Patients enrolled
Trial Details
Trial ID
NCT04439084
Start Date
March 6 2020
End Date
July 31 2021
Last Update
August 9 2021
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Arizona,
Phoenix, Arizona, United States, 85004
2
Mayo Clinic
Scottsdale, Arizona, United States, 85259
3
UCSF Fresno
Fresno, California, United States, 93701
4
University of Southern California
Los Angeles, California, United States, 90007